Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Mini Review
  • Published:

Transplantation for chronic myelogenous leukemia: yes, no, maybe so…an Oregon perspective

Bone Marrow Transplantation volume 32, pages 459–469 (2003)Cite this article

Summary:

Chronic myelogenous leukemia (CML) is a hematopoietic stem cell disorder in which allogeneic stem cell transplantation remains the only curative option, but its use is limited by donor availability and treatment-related morbidity and mortality. Imatinib mesylate is a targeted agent for CML with efficacy to date, which is superior to all other nontransplant therapy and has limited toxicity. The curative potential of imatinib remains to be proven and may be limited to a small number of patients. Optimal decision making regarding the use of these divergent therapies has not been defined. This paper reviews critical data relevant to these treatment options and provides an approach to current management of the CML patient.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Mauro MJ, O'Dwyer M, Heinrich MC, Druker BJ . STI571: a paradigm of new agents for cancer therapeutics. J Clin Oncol 2002; 20: 325–334.

    Article  CAS  PubMed  Google Scholar 

  2. Druker BJ, Tamura S, Buchdunger E, Ohno S et al. Effects of a selective inhibitor of the ABL tyrosine kinase on the growth of BCR-ABL positive cells. Nat Med 1996; 2: 561–566.

    Article  CAS  PubMed  Google Scholar 

  3. Kantarjian H, Sawyers C, Hochhaus A, Guilhot F et al. Imatinib (Gleevec™) results in sustained hematologic and cytogenetic responses among chronic-phase chronic myeloid leukemia (CML) failing interferon-alpha (IFN) – up to 31-month follow-up of 454 patients on phase II study. Blood 2002; 100: 94a (Abstr. 347).

    Google Scholar 

  4. Talpaz M, Silver RT, Druker BJ et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002; 99: 1928–1937.

    Article  CAS  PubMed  Google Scholar 

  5. Sawyers CL, Hochhaus A, Feldman E et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002; 99: 3530–3539.

    Article  CAS  PubMed  Google Scholar 

  6. O'Dwyer ME, Mauro MJ, Blasdel C et al. Lack of cytogenetic response is an adverse prognostic factor for relapse of chronic phase CML patients treated with imatinib mesylate (STI571). Blood 2001; 98: 137a (Abstr. 579).

    Google Scholar 

  7. Cortes J, Talpas M, O'Brien et al. Significance of lack of early cytogenetic (CG) response after therapy with imatinib mesylate in relation to later achievement of major or complete CB response in patients with Philadelphia chromosome-positive chronic myeloid leukemia. Blood 2002; 100: 787a (Abstr. 3113).

    Article  Google Scholar 

  8. Marin D, Bua M, Marktel S et al. The combination of cytogenetic response after 6 months treatment with STI571 and the presence of cytopenias in patients with CML in chronic phase resistant to or intolerant of interferon-alfa defines four different prognostic groups. Blood 2001; 98: 137a (Abstr. 3514).

    Article  Google Scholar 

  9. Sneed TB, Kantarjian HM, Talpaz M et al. Significance of myelosuppression (MS) during the course of therapy with imatinib in patients with chronic myelogenous leukemia (CML) in chronic phase. Blood 2002; 100: 787a (Abstr. 3110).

    Google Scholar 

  10. Mauro MJ, O'Dwyer ME, Kurilik G et al. Risk factors for myelosuppression in chronic phase CML patients treated with imatinib mesylate (STI571). Blood 2001; 98: 139a (#585).

    Google Scholar 

  11. O'Brien SG, Guilhot F, Larson R et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 11: 994–1004.

    Article  Google Scholar 

  12. Hughes T, Kaeda J, Branford S et al. Molecular responses to Imatinib (STI571) or Interferon+Ara-C as initial therapy for CML: results in the IRIS study. Blood 2002; 100: 93a (Abstr. 345).

    Google Scholar 

  13. Sokal JE, Cox EB, Baccarani M et al. Prognostic discrimination in ‘good-risk’ chronic granulocytic leukemia. Blood 1984; 63: 789–799.

    CAS  PubMed  Google Scholar 

  14. Hasford J, Pfirrmann M, Hehlmann R et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Wrtiting Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst 1998; 90: 850–858.

    Article  CAS  PubMed  Google Scholar 

  15. Baccarani M, Trabacchi E, Bassi S et al. Results of a phase II trial testing a combination of imatinib and pegylated α2b Interferon in PH+ chronic myeloid leukemia in early chronic phase. The early cytogenetic response is significantly risk related. By the Italian Cooperative Study Group on CML. Blood 2002; 100: 24a (Abstr. 348).

    Google Scholar 

  16. Druker BJ, O'Brien SG, Cortes J, Radich J . Chronic myelogenous leukemia. In: Hematology 2002 (Am Soc Hematol Educ Program) 2002, 111–1135.

    Article  Google Scholar 

  17. Horwitz MM, Rowlings PA, Passweg JR . Allogeneic bone marrow transplantation for CML: a report from the International Bone Marrow Transplant Registry. Bone Marrow Transplant 1996; 17 (Suppl. 3): S5–S6.

    Google Scholar 

  18. Kolb HJ, Mittermuller J, Clemm C, Holler E . Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990; 76: 2462–2465.

    CAS  PubMed  Google Scholar 

  19. Collins RH, Spielberg O, Drobyski W et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997; 15: 433–444.

    Article  PubMed  Google Scholar 

  20. Guglielmi C, Arcese W, Dazzi F et al. Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial dose. Blood 2002; 100: 397–405.

    Article  CAS  PubMed  Google Scholar 

  21. Clift RA, Buckner CD, Thomas ED et al. Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. Blood 1994; 84: 2036–2043.

    CAS  PubMed  Google Scholar 

  22. Lee SJ, Kuntz KM, Horowitz MM et al. Unrelated donor bone marrow transplantation for chronic myelogenous leukemia. Ann Intern Med 1997; 127: 1080–1088.

    Article  CAS  PubMed  Google Scholar 

  23. Hansen JA, Gooley TA, Martin PF et al. Bone marrow transplants from unrelated donors of patients with chronic myeloid leukemia. N Engl J Med 1998; 338: 962–968.

    Article  CAS  PubMed  Google Scholar 

  24. Morton AJ, Gooley T, Hansen JA et al. Association between pretransplant Interferon-α and outcome after unrelated donor marrow transplantation for chronic myelogenous leukemia in chronic phase. Blood 1998; 92: 394–401.

    CAS  PubMed  Google Scholar 

  25. Giralt S, Szydlo R, Goldman JM et al. Effect of short-term interferon therapy on the outcome of subsequent HLA-identical sibling bone marrow transplantation for chronic myelogenous leukemia: an analysis from the international bone marrow transplant registry. Blood 2000; 95: 410–415.

    CAS  PubMed  Google Scholar 

  26. Hehlmann R, Hochhaus A, Jans-Jochem K et al. Interferon-α before allogeneic bone marrow transplantation in chronic myelogenous leukemia does not affect outcome adversely, provided it is discontinued at least 90 days before the procedure. Blood 1999; 94: 3668–3677.

    CAS  PubMed  Google Scholar 

  27. Gratwohl A, Hermans J, Goldman JM et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Lancet 1998; 352: 1087–1092.

    Article  CAS  PubMed  Google Scholar 

  28. Or R, Shapira MY, Resnick I et al. Nonmyeloablative allogeneic stem cell tranpslantation for the treatment of chronic myeloid leukemia in first chronic phase. Blood 2003; 101: 444–445.

    Article  Google Scholar 

  29. Sandmaier BM, Hegenbart U, Shizuru J et al. Nonmyeloablative hematopoietic stem cell transplantation (SCT) from HLA-identical siblings for treatment of chronic myelogenous leukemia (CML): induction of molecular remissions. Blood 2001; 98: 371b (Abstr. 5259).

    Google Scholar 

  30. Crawley CR, Lalancette M, Szydlo R et al. Reduced intensity conditioned allografts for chronic myeloid leukaemia: a study from the chronic leukaemia working party of the EBMT. Blood 2002; 781a (Abstr. 3089).

  31. Hehlmann R, Berger U, Hochhaus A et al. Randomized comparison of early allogeneic related stem cell transplantation vs IFN-based therapy in newly diagnosed chronic myelogenous leukemia: first interim analysis of the German CML Study III. Blood 2001; 98: 728a (Abstr. 3036).

    Google Scholar 

  32. Olavarria E, Craddock C, Dazzi F et al. Imatinib mesylate (STI571) in the treatment of relapse of chronic myeloid leukemia after allogeneic stem cell transplantation. Blood 2002; 99: 3861–3862.

    Article  CAS  PubMed  Google Scholar 

  33. Kantarjian HM, O'Brien S, Cortes JE et al. Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood 2002; 100: 1590–1595.

    CAS  PubMed  Google Scholar 

  34. Chambon-Paulas C, Cony-Makhoul P, Giraudier S et al. Glivec (STI571) treatment for chronic myelogenous leukemia (CML) in relapse after allogeneic stem cell transplantation (SCT): a report of the French experience (On behalf of the SFGM and FILMC). Blood 2001; 98: 140 (Abstr. 587).

    Article  Google Scholar 

  35. Wassman B, Pfeifer H, Scheuring U et al. Glivec (STI571) in the treatment of patients with chronic myeloid leukemia (CML) relapsing in accelerated or blastic phase after allogeneic stem cell transplantations. Blood 2001; 98: 140 (Abstr. 588).

    Article  Google Scholar 

  36. Soiffer RJ, Galinsky I, DeAngelo D et al. Imatinib mesylate (Gleevec) for disease relapse following allogeneic bone marrow transplantation. Blood 2001; 98: 400 (Abstr. 682).

    Google Scholar 

  37. Ullmann AJ, Beck J, Koble K et al. Clinical and laboratory evaluation of patients treated with STI571 (Gleevec) after allogeneic and syngeneic stem cell transplantation with relapsed Philadelphia chromosome-positive leukemia. Blood 2001; 98: 401 (Abstr. 1685).

    Google Scholar 

  38. Hernandez-Boluda J-C, Carreras E, Cervantes F et al. Collection of Philadelphia-negative stem cells using recombinant human granulocyte colony-stimulating factor in chronic myeloid leukemia patients treated with α-interferon. Haematologica 2002; 87: 17–22.

    CAS  PubMed  Google Scholar 

  39. Olavarria E . Autotransplant for chronic myelogenous leukemia: is it useful? Haematologica 2002; 87: 3–5.

    PubMed  Google Scholar 

  40. Carella AM, Lerma E, Corsetti MT et al. Autografting with Philadelphia chromosome-negative mobilized hematopoietic progenitor cells in chronic myelogenous leukemia. Blood 1999; 93: 1534–1539.

    CAS  PubMed  Google Scholar 

  41. McGlave PB, De Fabritiis P, Deisseroth A et al. Autologous transplants for chronic myelogenous leukaemia: results from eight transplant groups. Lancet 1994; 343: 1486–1488.

    Article  CAS  PubMed  Google Scholar 

  42. Maziarz RT, Chauncey TR, Capdeville R et al. Growth factor mobilization of CD34+ PBSC in CML patients treated with imatinib (STI571). Blood 2001; 98: 738a (Abstr. 3078).

    Google Scholar 

  43. Choudhury A, Gajewski JL, Liang JC et al. Use of leukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against Philadelphia chromosome positive chronic myelogenous leukemia. Blood 1997; 89: 1133–1142.

    CAS  PubMed  Google Scholar 

  44. Kantarjian HM, Cortes J, O'Brien S et al. Effect of increasing imatinib mesylate (STI571) dose from 400 mg to 800 mg daily on outcome of patients (pts) with chronic phase Philadelphia chromosome positive chronic myelogenous leukemia (Ph+ CML CP). Blood 2001; 98: 137a (Abstr. 576).

    Google Scholar 

  45. Thiesing JT, Ohno-Jones S, Kolibaba KS, Druker BJ . Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells. Blood 2000; 96; 3195–3199.

    CAS  PubMed  Google Scholar 

  46. Perkins C, Kim CN, Fang G, Bhalla KN . Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-xL . Blood 2000; 95: 1014–1022.

    CAS  PubMed  Google Scholar 

  47. Porosnicu M, Nimmanapalli R, Nguyen D et al. Co-treatment with As2O3 enhances selective cytotoxic effects of STI-571 against Bcr-Abl-positive acute leukemia cells. Leukemia 2001; 15: 772–778.

    Article  CAS  PubMed  Google Scholar 

  48. La Rosée P, Johnson K, Corbin A et al. In-vitro efficacy of combined treatment depends on the underlying mechanism of resistance in imatinib resistant Bcr-Abl positive cell lines, submitted.

  49. Hoover R, Mahon FX, Melo JV et al. Overcoming STI571 resistance with the Farnesyltransferase inhibitor SCH6636. Blood 2001; 98: 617a (Abstr. 2585).

    Google Scholar 

  50. Martine G, Philippe R, Michel T et al. Imatinib (Gleevec®) and cytarabine (Ara-C) is an effective regimen in Philadelphia (Ph)-positive chronic myelogenous leukaemia (CML) chronic phase (CP) patients (pts). Blood 2002; 100: 95a (Abstr. 351).

    Google Scholar 

  51. Mauro MJ, O'Dwyer ME, Stone RM et al. Preliminary evaluation of the combination of imatinib mesylate (Gleevec) with low dose Ara-C as initial therapy for newly diagnosed chronic phase CML. Blood 2002; 100: 165a (#617).

    Google Scholar 

  52. O'Dwyer ME, Mauro MJ, Kuyl J et al. Preliminary evaluation of the combination of imatinib mesylate (Gleevec) in combination with low dose interferon-alpha for the treatment of chronic phase CML. Blood 2001; 98: 846a (#3513).

    Google Scholar 

  53. O'Brien S, Vallance SE, Craddock T et al. PEGIntron and STI571 combination evaluation study (PISCES) in chronic phase chronic myeloid leukaemia. Blood 2001; 98: 846a (Abstr. 3512).

    Google Scholar 

  54. Mauro MJ, Deininger MW, O'Dwyer ME et al. Phase I/II study of arsenic trioxide (Trisenox) in combination with imatinib mesylate (Gleevec, STI571) in patients with Gleevec-resistant chronic myelogenous leukemia in chronic phase. Blood 2002; 100: 781a (#3090).

    Google Scholar 

  55. Gotlib J, Dugan K, Katamneni U et al. Phase I/II study of farnesyltransferase inhibitor R115777 (Zarnestra) in patients with myeloproliferative disorders (MPDs): preliminary results. ASCO 2002; 4a Volume 21, Part 1 of 2 (#14).

  56. Goldman JM, Druker BJ . Chronic myeloid leukemia: current treatment options. Blood 2001; 98: 2039–2042.

    Article  CAS  PubMed  Google Scholar 

  57. Mauro MJ, Maziarz RT, Kuyl J et al. Increasing levels of detectable leukemia in imatinib treated CML patients with previously undetectable or very low levels of Bcr-Abl. ASCO 2003, submitted.

  58. Gotlib J, Cao T, Jones C et al. Serial real-time quantitative RT-PCR monitoring reveals frequent and rapid relapses after molecular remissions in chronic phase (CP) CML patients treated with imatinib mesylate (GLEEVEC™). Blood 2002; 100: 547a (#2151).

    Article  Google Scholar 

  59. O'Dwyer ME, Mauro MJ, Kurilik G et al. The impact of clonal evolution on response to imatinib mesylate (Gleevec) in accelerated phase CML. Blood 2002; 100: 1628–1633.

    Article  CAS  PubMed  Google Scholar 

  60. O'Dwyer M, Gatter K, Loriaux M et al. The demonstration of clonal abnormalities in Philadelphia chromosome negative cells following imatinib mesylate induced major cytogenetic response in patients with chronic myeloid leukemia. Leukemia 2003; 17: 481–487.

    Article  CAS  PubMed  Google Scholar 

  61. Bumm T, Mueller C, Leiblein S et al. Restoration of polyclonal hematopoiesis in most CML patients in complete cytogenetic remission to imatinib but rapid emergence of clonal cytogenetic abnormalities in Ph-negative cells in a subset of patients. Blood 2002; 100: 164a (#613).

    Google Scholar 

  62. Medina J, Kantarjian H, Talpaz M et al. Chromosomal abnormalities in Philadelphia chromosome (Ph) negative metaphases appearing during treatment with imatinib mesylate in patients (pts) with Ph positive chronic myeloid leukemia (CML) in chronic phase (CP). Blood 2002; 100: 368a (#1423).

    Google Scholar 

  63. Deininger MW, Schleuning M, Sayer HG et al. Allografting after imatinib therapy: no evidence for increased transplant-related mortality and favorable results in patients transplanted in remission; a retrospective study by the EBMT. Blood 2002; 100: 783a (#3097).

    Google Scholar 

  64. Shimoni A, Kroger N, Zander A et al. Imatinib mesylate (STI571) in preparation for allogenic hematopoetic stem cell transplantation and donor leukocyte infusions in patients with Philadelphia positive acute leukemias. Leukemia 2003; 17: 290–297.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank Dr Brian Druker for the multiple discussions on treatment strategies, Drs Philip McCarthy, Jose Leis and Aleksandra Sinic for their critical review of this manuscript, and Ms Paulette Wakeman and Ms Michelle Faford for assistance in its preparation.

Author information

Authors and Affiliations

  1. Bone Marrow Transplantation Program/Leukemia Center, Center for Hematologic Malignancies, Oregon Cancer Institute, Oregon Health & Science University, Portland, OR, USA

    Richard T Maziarz & Michael J Mauro

Authors
  1. Richard T Maziarz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael J Mauro
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Maziarz, R., Mauro, M. Transplantation for chronic myelogenous leukemia: yes, no, maybe so…an Oregon perspective. Bone Marrow Transplant 32, 459–469 (2003). https://doi.org/10.1038/sj.bmt.1704163

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1704163

Keywords

This article is cited by

Search

Advanced search

Quick links